Article
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2013
Kobayashi Susumu, Canepa Hannah M, Bailey Alexandra S, Nakayama Sohei, Yamaguchi Norihiro, Goldstein Michael A, Huberman Mark S, Costa Daniel B
Abstract excerpt
BACKGROUND: Non-small-cell lung cancers (NSCLCs) containing EGFR mutations are exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This is the case of the most common EGFR mutations affecting exon 18 (G719X), 19 (inframe deletions), and 21 (L858R and L861Q). However, the frequency of compound (i.e., double or complex) EGFR mutations-where an EGFR TKI sensitizing or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.